Oncology Europe
Market Access Canada
Challenges in the Shift to Payer Marketing and Engagement
The cost of employing a sales force to distribute clinical data, marketing information and drug samples to very large numbers of physicians has become unsustainable. Building and maintaining effective working relationships with physicians has been estimated to cost tens of thousands of dollars per physician in the U.S.(1).
Free Trade Agreement Could Prioritize Commercial Interests Over Public Services
The campaigning groups, whose letter was addressed to President Barack Obama, EC President José Manuel Barroso, and European Council President Herman Van Rompuy,fear that the Transatlantic Trade and Investment Partnership (TTIP) may damage public services in favor of commercial interests, by, among other things, introducing investor protection measures which would enable corporations to sue a government that acts in a way that endangers profits.
FDA Continues To Delay Merck Drug To Reverse Anesthesia
The announcement reported by Reuters followed a cancelled meeting of outside advisers by the FDA. Merck said the FDA had told them they needed additional time to assess the results of its recently completed inspection of one of the company's clinical trial sites.
A Payer View On Pricing and Reimbursement in Italy
Within the European Union the policy for pharmaceuticals focuses on linking a high level of public health with innovation, ultimately aiming to ensure that Europeans continue to benefit from new medicines. This suggests that market access conditions for manufacturers within individual Member States should be relatively smooth.
Free Webinar: Create Perfect Value Propositions
US Deals Delay 20 Blockbuster Generics up to Nine Years
These deals have kept generic versions of patented meds off the market for an average of five years, and in some cases as many as nine years, allowing branded drug companies to rack up $98 billion in sales, says the report from Community Catalyst and the US Public Interest Research Group (USPIRG). Moreover, the findings are described in the report as “just the tip of the iceberg.”
Trade Agreement Won’t Affect Public Health According to EC Officials
At a private meeting in Brussels on 16th July, European Commission officials briefed non-governmental organizations and civil society representatives on the outcome of the opening negotiations held in Washington, DC, on 8 July. They assured that the public health sector was not discussed in the first round of talks, but also that there was no plan for it to be included in any following rounds of negotiations, despite earlier claims that the talks will include all subjects.
The Route to Market Access in Mexico
According to Rafael, the main criterion used by Mexico’s national regulatory agency COFEPRIS to assess new medications is cost-containment. This means that “pharma companies will need to be prepared with pharmacoeconomic studies showing how the drug stands out from those already on the market.”
Exclusive: Richard Bergström Explains Transatlantic Joint Principles for Clinical Data Sharing
Speaking exclusively to eyeforpharma, Richard Bergström, EFPIA Director General, explains the intentions of the joint position document, discusses continuing concerns over privacy and his hopes that industry and legislators can collaborate on the best way forward for transparency…
UPDATED Exclusive: The Devil is in the Details – How The Guardian's Bias Towards One Leaked Memo Proves Greater Transparency is Needed From All
On Wednesday, 24thJuly, EFPIA and PhRMA responded to the ongoing argument with a joint set of new principles aimed at addressing these transparency concerns. Speaking exclusively to eyeforpharma, Richard Bergström, EFPIA Director General, explains the intentions of the joint position document and the real story behind that leaked memo….
European Commission Launch Inquiry Into Alleged Aid To German Pharma Companies
The Commission is investigating German law on rebates for pharmaceutical companies facing financial problems. Based on Council Directive 89/105/EEC which allows Member States to impose a price freeze on medicinal products, Germany introduced an obligatory manufacturer's rebate of 16 per cent to be granted by producers of certain prescription medicines to public sickness funds and private health insurers between 1 August 2010 and 31 December 2013.
252% Increase in M&A Activity Since First Quarter in 2013
Through ‘The Health Care M&A report’, Irving Levin Associates demonstrates that the original total spend for health care M&A activity in the second quarter of 2013 was $52.6 billion, an increase of $37.7 billion from the first period of this financial year. When compared with second quarter of 2012, deal value was steady in the same period for this year although its volume increased by 10% since the previous period.
Why Pharma Should Think Big And Act Small
Some companies seem to get too big to be effective, where mergers can often reduce shareholder values as efficiencies tend to disappear, this raises the question: just how big is too big?
AstraZeneca Increases Chinese Investment Despite Industry Scrutiny
A Local Flavor will Bring You Sales Success in Brazil
Novartis – Owning Responsibility for Payer Relations
The Formulary – Your Key to Mexican Market Access
“We need to find a way to prioritize by considering what the main public health concerns are, what drugs or treatments will change disease history in terms of mortality and morbidity, and what things as a country we need to search for."